1. Home
  2. IMSR vs SGHT Comparison

IMSR vs SGHT Comparison

Compare IMSR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terrestrial Energy Inc.

IMSR

Terrestrial Energy Inc.

N/A

Current Price

$3.26

Market Cap

400.4M

Sector

N/A

ML Signal

N/A

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

N/A

Current Price

$8.83

Market Cap

469.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMSR
SGHT
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
400.4M
469.9M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
IMSR
SGHT
Price
$3.26
$8.83
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
★ $11.67
$9.40
AVG Volume (30 Days)
★ 1.3M
279.2K
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 28.16
EPS
★ N/A
N/A
Revenue
$248,357.00
★ $77,363,000.00
Revenue This Year
N/A
$16.79
Revenue Next Year
N/A
$11.86
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.32
$3.22
52 Week High
$16.38
$9.71

Technical Indicators

Market Signals
Indicator
IMSR
SGHT
Relative Strength Index (RSI) 28.32 57.30
Support Level N/A $7.70
Resistance Level $5.69 $9.71
Average True Range (ATR) 0.23 0.43
MACD -0.05 -0.07
Stochastic Oscillator 2.03 55.00

Price Performance

Historical Comparison
IMSR
SGHT

About IMSR Terrestrial Energy Inc.

Terrestrial Energy Inc develops Generation IV nuclear power plants based on its proprietary Integral Molten Salt Reactor (IMSR) technology. Its small modular reactor plants are designed to provide low-carbon electricity and high-temperature industrial heat for applications including power generation, petrochemical and chemical processing, and data centers. The company is working with regulators, suppliers, industrial partners, and energy users to develop, license, and commission IMSR plants.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: